BIOCRYST PHARMACEUTICALS, INC. Debt Securities, Available-for-sale
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Debt Securities, Available-for-sale of $197.60 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale $197.60M.
- 2026-03-31: Debt Securities, Available-for-sale $87.38M.
- 2025-12-31: Debt Securities, Available-for-sale $246.18M.
- 2025-09-30: Debt Securities, Available-for-sale $168.46M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $197.60M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $87.38M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $246.18M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $168.46M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $182.11M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $210.45M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $236.46M 10-K · filed 2026-02-26 |
| 2024-09-30 | $252.60M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $257.93M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $252.22M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $278.34M 10-K · filed 2025-02-25 |
| 2023-09-30 | $246.69M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $267.90M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $246.45M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $137.62M 10-K · filed 2024-02-27 |
| 2022-09-30 | $214.29M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $144.91M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $47.96M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $10.04M 10-K · filed 2023-02-27 |
| 2021-09-30 | $28.24M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $8.11M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $13.45M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $28.24M 10-K · filed 2022-02-28 |
| 2020-09-30 | $49.83M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $15.94M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $11.19M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $22.05M 10-K · filed 2021-03-01 |
| 2019-09-30 | $38.53M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $62.13M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $84.41M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $100.11M 10-K · filed 2020-03-13 |
| 2018-09-30 | $96.89M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $87.38M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $89.14M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $105.41M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |